Update on Highly Pathogenic Avian Influenza A(H5N1) Virus for Clinicians and Healthcare Centers

At a glance

During this COCA Call, presenters will give an update on the current outbreak in the United States and current CDC surveillance and monitoring efforts. They will also provide information for clinicians on testing, using antivirals, and infection prevention and control recommendations.

Webinar

View slides
View transcript

Free Continuing Education

Overview

Highly Pathogenic Avian Influenza (HPAI) (H5N1) virus is widespread among wild birds and continues to cause outbreaks in poultry and spillover to mammals. In March 2024, HPAI A(H5N1) virus was detected in dairy cattle. To date, there have been three human cases of HPAI A(H5N1) virus infection identified in dairy farm workers in the United States. The risk to the public from HPAI A(H5N1) viruses is low; however, people who have job-related or recreational exposure to infected birds or animals, including dairy cattle, are at greater risk of HPAI A(H5N1) virus infection. During this COCA Call, presenters will give an update on the current outbreak in the United States and current CDC surveillance and monitoring efforts. They will also provide information for clinicians on testing, using antivirals, and infection prevention and control recommendations.

Presenters

Alicia Budd, MPH
Team Lead
National Surveillance and Outbreak Response Team
Epidemiology and Prevention Branch
Influenza Division
National Center for Immunization and Respiratory Diseases
Centers for Disease Control and Prevention

Ryan Fagan, MD, MPH&TM
Medical Officer
Prevention and Response Branch
Division of Healthcare Quality Promotion
National Center for Emerging and Zoonotic Infectious Diseases
Centers for Disease Control and Prevention

Tim Uyeki, MD, MPH, MPP
Chief Medical Officer
Influenza Division
National Center for Immunization and Respiratory Diseases
Centers for Disease Control and Prevention

Call Objectives

COCA Call Objectives

At the conclusion of the session, the participant will be able to accomplish the following:

  1. Cite background information on the topic covered during the presentation.
  2. Discuss CDC's role in the topic covered during the presentation.
  3. Describe the topic's implications for clinicians.
  4. Discuss concerns and/or issues related to preparedness for and/or response to urgent public health threats.
  5. Promote health improvement, wellness, and disease prevention in cooperation with patients, communities, at-risk populations, and other members of an interprofessional team of healthcare providers.

Activity-Specific Objectives

  1. Discuss the epidemiology and clinical features of human cases of HPAI A(H5N1) virus infection.
  2. Describe risk of human infection with HPAI A(H5N1) viruses, identify higher risk populations, and what to assess in clinical settings.
  3. Describe testing, using antivirals, and infection prevention and control recommendations for patients with HPAI A(H5N1) virus infection.

Continuing Education

Instructions for Obtaining Continuing Education (CE)

To receive continuing education (CE) for WC4520R-071624—Update on Highly Pathogenic Avian Influenza A(H5N1) Virus for Clinicians and Healthcare Centers, please visit CDC TRAIN and search for the course in the Course Catalog using WC4520R-062724. Follow the steps below by August 19, 2024. The registration code is COCA071624.

To receive continuing education (CE) for WD4520R-071624—Update on Highly Pathogenic Avian Influenza A(H5N1) Virus for Clinicians and Healthcare Centers, please visit CDC TRAIN and search for the course in the Course Catalog using WD4520R-071624. Follow the steps below between August 20, 2024, and August 20, 2026.

  1. Register for and complete the course.
  2. Pass the post-assessment at 75%.
  3. Complete the evaluation.
  4. Visit Your Learning to access your certificates and transcript.

Accreditation Statements

In support of improving patient care, The Centers for Disease Control and Prevention is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Jointly Accredited Provider logo
CDC is a Jointly Accredited Provider for Interprofessional Continuing Education.

CME: The Centers for Disease Control and Prevention designates this live activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA CME: Credit Designation Statement – Live
The Centers for Disease Control and Prevention has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

CNE: The Centers for Disease Control and Prevention designates this activity for 1 nursing contact hours.

CPE: The Centers for Disease Control and Prevention designated this Knowledge-based event for pharmacists to receive 0.1 CEUs in pharmacy education. The Universal Activity Number is JA4008229-0000-23-099-L04-P and enduring is JA4008229-0000-23-100-H04-P.

CEU: The Centers for Disease Control and Prevention is authorized by IACET to offer 0.1 CEUs for this program.

CECH: Sponsored by the Centers for Disease Control and Prevention, a designated provider of continuing education contact hours (CECH) in health education by the National Commission for Health Education Credentialing, Inc. This program is designated for Certified Health Education Specialists (CHES®) and/or Master Certified Health Education Specialists (MCHES®) to receive up to 1 total Category I continuing education contact hours. Maximum advanced level continuing education contact hours available are 1. Continuing Competency credits available are 1. CDC provider number 98614.

AAVSB/RACE: This program has been submitted (but not yet approved) for 1 hours of continuing education credit in jurisdictions which recognize AAVSB RACE approval; however, participants should be aware that some boards have limitations on the number of hours accepted in certain categories or restrictions on certain methods of delivery of continuing education.

For Certified Public Health Professionals (CPH): The Centers for Disease Control and Prevention is a pre-approved provider of Certified in Public Health (CPH) recertification credits and is authorized to offer 1 CPH recertification credits for this program.

DISCLOSURE: In compliance with continuing education requirements, all planners and presenters/moderators must disclose all financial relationships, in any amount, with ineligible companies over the previous 24 months as well as any use of unlabeled product(s) or products under investigational use.

CDC, our planners, presenters, and moderators wish to disclose they have no financial relationship(s) with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Content will not include any discussion of the unlabeled use of a product or a product under investigational use with the exception of Dr. Tim Uyeki who will discuss using oseltamivir at higher dosing for post-exposure prophylaxis than for controlling seasonal influenza.

CDC did not accept financial or in-kind support from ineligible companies for this continuing education activity.

Target Audience

  • Physicians
  • Nurses
  • Pharmacists
  • Veterinarians
  • Physician Assistants
  • Health Educators
  • Other Clinicians

Additional Information

  • Contact Information: coca@cdc.gov
  • Support/Funding: Centers for Disease Control and Prevention, Office of Emergency Risk Communication
  • Method of Participation: You may participate in the educational activity by viewing the program information above.
Print
Content Source: